A hyperinflammation clinical risk tool, HI5-NEWS2, stratifies hospitalised COVID-19 patients to associate risk of death and effect of early dexamethasone in an observational cohort
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0280079 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PLOS ONE, 2023. Verfasst von Michael R Ardern-Jones und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Experimental Sciences, University of Southampton Faculty of Medicine, Sir Henry Wellcome Laboratories, Southampton General Hospital, Southam…. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The success of early dexamethasone therapy for hospitalised COVID-19 cases in treatment of Sars-CoV-2 infection may predominantly reflect its anti-inflammatory action against a hyperinflammation (HI) response. It is likely that there is substantial heterogeneity in HI responses in COVID-19.
Methods
Blood CRP, ferritin, neutrophil, lymphocyte and platelet counts were scored to assess HI (HI5) and combined with a validated measure of generalised medical deterioration (NEWS2) before day 2. Our primary outcome was 28 day mortality from early treatment with dexamethasone stratified by HI5-NEWS2 status.
Findings
Of 1265 patients, high risk of HI (high HI5-NEWS2) (n = 367, 29.0%) conferred a strikingly increased mortality (36.0% vs 7.8%; Age adjusted hazard ratio (aHR) 5.9; 95% CI 3.6–9.8, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Experimental Sciences, University of Southampton Faculty of Medicine, Sir Henry Wellcome Laboratories, Southampton General Hospital, Southampton, United Kingdom.
- Division of Medicine, University Hospitals Southampton NHS Foundation Trust, Southampton General Hospital, Southampton, United Kingdom.
- NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
- Clinical Informatics Research Unit Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
- Department of Primary Care, Population Sciences and Medical Education, University of Southampton, Southampton, United Kingdom.
- Department of Respiratory Medicine, University Hospitals Southampton NHS Foundation Trust, Southampton, United Kingdom.
ORCID-Profile: Michael R Ardern-Jones
Zitieren
APA
Ardern-Jones, M. R., Phan, H. T. T., Borca, F., Stammers, M., Batchelor, J., Reading, I. C., Fletcher, S. V., Smith, T., & Duncombe, A. S. (2023). A hyperinflammation clinical risk tool, HI5-NEWS2, stratifies hospitalised COVID-19 patients to associate risk of death and effect of early dexamethasone in an observational cohort. PLOS ONE. https://doi.org/10.1371/journal.pone.0280079
Vancouver
Ardern-Jones MR, Phan HTT, Borca F, Stammers M, Batchelor J, Reading IC, et al. A hyperinflammation clinical risk tool, HI5-NEWS2, stratifies hospitalised COVID-19 patients to associate risk of death and effect of early dexamethasone in an observational cohort. PLOS ONE. 2023. doi:10.1371/journal.pone.0280079
BibTeX
@article{ArdernJones2023,
author = {Ardern-Jones, Michael R and Phan, Hang T T and Borca, Florina and Stammers, Matt and Batchelor, James and Reading, Isabel C and Fletcher, Sophie V and Smith, Trevor and Duncombe, Andrew S},
title = {A hyperinflammation clinical risk tool, HI5-NEWS2, stratifies hospitalised COVID-19 patients to associate risk of death and effect of early dexamethasone in an observational cohort},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0280079}
}
EUVIMED